List of Saxenda drug patents

Saxenda is owned by Novo.

Saxenda contains Liraglutide Recombinant.

Saxenda has a total of 44 drug patents out of which 8 drug patents have expired.

Expired drug patents of Saxenda are:

  • US8672898
  • US9486588
  • US8846618
  • US6899699*PED
  • US9486588*PED
  • US8672898*PED
  • US8846618*PED
  • US6268343

Saxenda was authorised for market use on 23 December, 2014.

Saxenda is available in solution;subcutaneous dosage forms.

Saxenda can be used as method for chronic weight management by treating obesity, cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease.

The generics of Saxenda are possible to be released after 09 July, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(5 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 25 days ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 25 days ago)

US8846618 NOVO Stable formulation of modified GLP-1
Jun, 2022

(7 months ago)

US6899699

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(6 months ago)

US9486588

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(6 months ago)

US8672898

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(6 months ago)

US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1
Dec, 2022

(a month ago)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(25 days from now)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(5 months from now)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(11 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(1 year, 3 months from now)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(1 year, 9 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(3 years from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Apr, 2026

(3 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Jul, 2026

(3 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(3 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(3 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(3 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(3 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(3 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jan, 2027

(3 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Feb, 2027

(4 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(4 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Aug, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(4 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Mar, 2028

(5 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(9 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(9 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(13 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic